Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 981 to 990 of 1535 total matches.

Genvoya - A New 4-Drug Combination for HIV

   
The Medical Letter on Drugs and Therapeutics • Feb 15, 2016  (Issue 1488)
improvements in BMD at the spine (+1.56% vs -0.44%) and hip (+1.47% vs -0.34%).7 20 The Medical Letter ® Vol ...
The FDA has approved Genvoya (Gilead), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir alafenamide, for treatment of HIV-1 infection in patients ≥12 years old. This is the first approval for tenofovir alafenamide (TAF), a tenofovir prodrug. Stribild, a fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (TDF), was approved in 2012.
Med Lett Drugs Ther. 2016 Feb 15;58(1488):19-21 |  Show IntroductionHide Introduction

Lesinurad (Zurampic) for Gout-Associated Hyperuricemia

   
The Medical Letter on Drugs and Therapeutics • Nov 21, 2016  (Issue 1508)
The Medical Letter ® Vol. 58 (1508) November 21, 2016 DRUG INTERACTIONS — Lesinurad is metabolized by CYP2C9 ...
The FDA has approved lesinurad (Zurampic – Ironwood), a uric acid transporter 1 (URAT1) inhibitor, for adjunctive treatment of gout-associated hyperuricemia in patients whose serum uric acid levels fail to reach goal with xanthine oxidase inhibitor monotherapy.
Med Lett Drugs Ther. 2016 Nov 21;58(1508):148-50 |  Show IntroductionHide Introduction

Inflectra - An Infliximab Biosimilar

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017  (Issue 1513)
, and then every 8 weeks was compared to the same dosage of 24 The Medical Letter ® Vol. 59 (1513) January 30 ...
The FDA has approved infliximab-dyyb (Inflectra – Pfizer; marketed as Remsima in some countries), as a biosimilar of the TNF inhibitor infliximab (Remicade). Infliximab-dyyb was approved in the European Union (EU) in 2013 and in Canada in 2014. It is the second biosimilar to be approved by the FDA. Filgastrim-sndz (Zarxio), a recombinant human granulocyte colony-stimulating factor, was the first.
Med Lett Drugs Ther. 2017 Jan 30;59(1513):23-5 |  Show IntroductionHide Introduction

Lofexidine (Lucemyra) for Opioid Withdrawal

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018  (Issue 1551)
discontinuation of lofexidine, however, can cause marked rebound hypertension. 116 The Medical Letter ® Vol. 60 ...
The FDA has approved lofexidine (Lucemyra – US WorldMeds/Salix), a centrally acting alpha2 receptor agonist, to manage withdrawal symptoms in adults abruptly stopping opioid use. Available in the UK since 1992, lofexidine is the first nonopioid to be approved in the US for management of opioid withdrawal symptoms. Clonidine (Catapres, and generics), another central alpha2 receptor agonist, has been used off-label for this indication for many years.
Med Lett Drugs Ther. 2018 Jul 16;60(1551):115-7 |  Show IntroductionHide Introduction

Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019  (Issue 1563)
The Medical Letter ® Vol. 61 (1563) January 14, 2019 guselkumab, tildrakizumab has not been associated ...
Tildrakizumab-asmn (Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is the second selective IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) was the first.
Med Lett Drugs Ther. 2019 Jan 14;61(1563):4-6 |  Show IntroductionHide Introduction

Dupilumab (Dupixent) for Asthma

   
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019  (Issue 1563)
was effective irrespective of baseline blood 7 The Medical Letter ® Vol. 61 (1563) January 14, 2019 ...
The FDA has approved the subcutaneously injected monoclonal antibody dupilumab (Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of patients ≥12 years old with moderate to severe asthma with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupilumab was approved earlier to treat adults with moderate to severe atopic dermatitis inadequately controlled with topical therapies.
Med Lett Drugs Ther. 2019 Jan 14;61(1563):6-8 |  Show IntroductionHide Introduction

Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019  (Issue 1566)
of this material is strictly prohibited. For further information call: 800-211-2769 27 The Medical Letter ® Vol ...
Since 2008, because of safety concerns, the FDA has mandated that long-term cardiovascular outcomes trials be conducted for all new drugs for type 2 diabetes. Reductions in the incidence of macrovascular complications in these trials with some sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists in patients at risk for cardiovascular disease (see Table 1) have led to new recommendations.
Med Lett Drugs Ther. 2019 Feb 25;61(1566):26-8 |  Show IntroductionHide Introduction

Prucalopride (Motegrity) for Chronic Idiopathic Constipation

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
The Medical Letter ® Vol. 61 (1573) June 3, 2019 ADVERSE EFFECTS — In the 6 placebo-controlled clinical ...
The FDA has approved the 5-HT4 receptor agonist prucalopride (Motegrity – Shire) for treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride is the only drug currently approved in the US for treatment of CIC that stimulates colonic peristalsis. It has been available in Europe and Canada for several years.
Med Lett Drugs Ther. 2019 Jun 3;61(1573):86-8 |  Show IntroductionHide Introduction

Colorectal Cancer Screening

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019  (Issue 1575)
or 2 first-degree relatives of any age. 98 The Medical Letter ® Vol. 61 (1575) July 1, 2019 than ...
Most colorectal cancers arise from localized adenomatous polyps in a process that may take 10 years or more. Early detection and removal of a precancerous colonic lesion (polyp) can prevent cancer from developing.
Med Lett Drugs Ther. 2019 Jul 1;61(1575):97-9 |  Show IntroductionHide Introduction

Benzhydrocodone/Acetaminophen (Apadaz) for Pain

   
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019  (Issue 1576)
administration of 2 crushed tablets, hydrocodone 111 The Medical Letter ® Vol. 61 (1576) July 15, 2019 ...
The FDA has approved Apadaz (KemPharm), a short-acting, fixed-dose combination of benzhydrocodone and acetaminophen, for short-term management (≤14 days) of acute pain severe enough to require an opioid and for which alternative treatment options are inadequate. Benzhydrocodone is a prodrug of hydrocodone. Fixed-dose combinations of short-acting hydrocodone and acetaminophen or ibuprofen have been available for years and are the most abused opioid products in the US. Apadaz was developed under the presumption that inclusion of the inactive prodrug would reduce the potential for...
Med Lett Drugs Ther. 2019 Jul 15;61(1576):110-2 |  Show IntroductionHide Introduction